成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. MAPK/ERK Pathway Autophagy Anti-infection
  3. MEK Autophagy Mitophagy Influenza Virus
  4. U0126-EtOH

U0126-EtOH 是一種有效，非 ATP 競爭性的，選擇性的 MEK1 和 MEK2 抑制劑，IC50 分別為 72 nM 和 58 nM。U0126-EtOH 是一種自噬 (autophagy) 和線粒體自噬 (mitophagy) 抑制劑。

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務

U0126-EtOH Chemical Structure

U0126-EtOH Chemical Structure

CAS No. : 1173097-76-1

1.  客戶無需承擔相應的運輸費用。

2.  同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥850
In-stock
5 mg ￥468
In-stock
10 mg ￥750
In-stock
20 mg ￥1200
In-stock
50 mg ￥2100
In-stock
100 mg ￥3464
In-stock
200 mg ￥5044
In-stock
500 mg   詢價  
1 g   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of U0126-EtOH:

MCE 顧客使用本產(chǎn)品發(fā)表的 382 篇科研文獻

WB
RT-PCR
IHC

    U0126-EtOH purchased from MCE. Usage Cited in: Biochem Pharmacol. 2023 Mar 7;115489.  [Abstract]

    U0126 (20 uM; pretreat for 2 h) rescues the loss of UHRF1/DNMT1 expression and the increase of E-Cadherin expression that induced by Lenvatinib in Huh7 cells.

    U0126-EtOH purchased from MCE. Usage Cited in: Mol Cell Endocrinol. 2023 Feb 17;111891.  [Abstract]

    U0126 (10 uM; pre-treate for 1 h) attenuates IL-1-induced upregulation of COX-2 expression in KGN cells.

    U0126-EtOH purchased from MCE. Usage Cited in: Cancer Res. 2019 Sep 1;79(17):4466-4479.  [Abstract]

    Western blot and IHC analyses for p-ERK1/2 in lung tissues after vehicle or U0126 treatment.

    U0126-EtOH purchased from MCE. Usage Cited in: Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F660-F673.  [Abstract]

    Western analysis of α-SMA, Collagen I and E-cadherin protein expression in the treatment of U0126 with different concentrations.

    U0126-EtOH purchased from MCE. Usage Cited in: Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F660-F673.  [Abstract]

    Western analysis of Vimentin, E-cadherin and Snail1 protein expression with or without the treatment of U0126.

    U0126-EtOH purchased from MCE. Usage Cited in: J Cell Biochem. 2019 Jan;120(1):321-331.  [Abstract]

    U0126 enhances the negative effect of Fsk-IBMX on the development of glioma stem cells (GSCs).

    U0126-EtOH purchased from MCE. Usage Cited in: Acta Biochim Biophys Sin (Shanghai). 2019 Apr 1;51(4):365-374.  [Abstract]

    MAPKs inhibitors suppress LPS-induced COX-2 expression and AKT1 phosphorylation. RAW264.7 cells are pretreated for 1 h with U0126, SB202190, SP600125 alone, or all the three inhibitors, respectively, and then exposed to 40 ng/ml LPS for 30 min or 12 h. The phosphorylated protein kinases and COX-2 expression are detected by western blot analysis using their corresponding antibodies.

    U0126-EtOH purchased from MCE. Usage Cited in: Blood. 2018 Jul 12;132(2):210-222.  [Abstract]

    Phosphorylation of p-ERK1/2 and p-Akt in MKs pretreated with 0.5 μM NVP-ADW742, 10 μM U0126 or 20 μM LY294002 followed by rhIGF-1 treatment for 15 minutes.

    U0126-EtOH purchased from MCE. Usage Cited in: Biomaterials. 2018 Sep;178:95-108.  [Abstract]

    U0126 effectively inhibits the phosphorylation of ERK, leading to the inhibition of IL-10 production.

    U0126-EtOH purchased from MCE. Usage Cited in: Cancer Lett. 2018 Aug 28;430:201-214.  [Abstract]

    Inhibition of ERK suppresses N-cadherin expression. CD146WT or CD146KO MEFs are stimulated with or without TGF-β1 (10?ng/mL) for 24?h in the presence or absence of U0126 (2?μM). The expression and activation of ERK and the expression of E-cadherin and N-cadherin is assessed by immunoblotting.

    U0126-EtOH purchased from MCE. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291.  [Abstract]

    Blocking the three MAPK signaling pathways through specific inhibitors (U0126; SB202190; and SP600125) significantly decrease the infection-induced neuroinflammatory response via real-time PCR analysis.

    U0126-EtOH purchased from MCE. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291.  [Abstract]

    Blocking the three MAPK signaling pathways through specific inhibitors (U0126; SB202190; and SP600125) significantly decrease the infection-induced neuroinflammatory response via real-time PCR analysis.

    U0126-EtOH purchased from MCE. Usage Cited in: J Neuroinflammation. 2018 Jun 15;15(1):184.  [Abstract]

    Representative immunoblots of total lysates from BV2 cells treated with MPP+or/and U0126 (10 μM), SP600125 (SP, 10 μM) and SB203580 (SB, 10 μM) using the antibodies against DICER.

    U0126-EtOH purchased from MCE. Usage Cited in: Cell Death Dis. 2018 Oct 3;9(10):1015.  [Abstract]

    Representative western blot images are showing the LC3, and the phosphorylated and total protein expression of Akt and ERK1/2 after treatment with H2O2 in the presence and absence of MK2206 (5?μM) and U0126 (25?μM).

    U0126-EtOH purchased from MCE. Usage Cited in: Cell Death Dis. 2018 Feb 15;9(3):269.  [Abstract]

    WB is used to detect the effect of EGF treatment on the expression of YAP with the inhibitors of EGFR or its downsream members.

    U0126-EtOH purchased from MCE. Usage Cited in: Phytomedicine. 2018 Mar 15;42:152-163.  [Abstract]

    Cells are pretreated with SP600125 (20 μM), SB203580 (20 μM) or U0126 (20 μM) in presence or absence of KLA, then incubated with LPS (1 μg/mL) for certain time. Cell lysates are subjected to western blot.

    U0126-EtOH purchased from MCE. Usage Cited in: Biomed Pharmacother. 2018 Feb 19;100:417-425.  [Abstract]

    HaCaT cells are pre-incubated with Compound C (CC) (10 μM) and U0126 (10 μM), pharmacological inhibitors of AMPKα, ERK, respectively, for 1 h before treatment with DA8 and DA14 (DAs).

    U0126-EtOH purchased from MCE. Usage Cited in: Biomed Pharmacother. 2018 Oct 3;108:1294-1302.  [Abstract]

    The protein levels of IL-1β and TNF-α are sharply downregulated by the addition of inhibitors SB203580, SP600125, and U0126.

    U0126-EtOH purchased from MCE. Usage Cited in: Biomed Pharmacother. 2018 Oct 3;108:1294-1302.  [Abstract]

    As for both 0 g and 3 g groups, the p-ERK1/2/ERK1/2 is notably reduced by inhibitors SB203580, SP600125, and U0126.

    U0126-EtOH purchased from MCE. Usage Cited in: Biomed Pharmacother. 2018 Oct 3;108:1294-1302.  [Abstract]

    As for both 0 g and 3 g groups, the p-JNK1&JNK1 is downregulated by inhibitors SB203580, SP600125, and U0126.

    U0126-EtOH purchased from MCE. Usage Cited in: Biomed Pharmacother. 2018 Oct 3;108:1294-1302.  [Abstract]

    The protein level of MMP-9 is downregulated by inhibitors SB203580, SP600125, and U0126.

    U0126-EtOH purchased from MCE. Usage Cited in: Biomed Pharmacother. 2018 Oct 3;108:1294-1302.  [Abstract]

    As for both 0 g and 3 g groups, the p-p38&p38 is downregulated by inhibitors SB203580, SP600125, and U0126.

    U0126-EtOH purchased from MCE. Usage Cited in: Front Immunol. 2018 Dec 7;9:2854.  [Abstract]

    Neutrophils are pretreated with inhibitor of p38 MAPK (SB203580) and ERK1/2 (U0126), and the cells are then incubated with either SS2 ZY05719 or PMA for 3 h. Immunofluorescence is performed.

    U0126-EtOH purchased from MCE. Usage Cited in: Reprod Biol Endocrinol. 2018 May 31;16(1):55.  [Abstract]

    Western blot analysis of claudin 5, occludin and ZO-1 in TM4 cells, cells are treated with 100 nM Leptin or pre-treated with different inhibitors following a 100 nM Leptin treatment.

    U0126-EtOH purchased from MCE. Usage Cited in: J Cell Biochem. 2018 Sep 19.  [Abstract]

    Western blot shows the expression of p-ERK and MMP13 with the treatment of U0126 and CCL17.

    U0126-EtOH purchased from MCE. Usage Cited in: Mol Med Rep. 2018 Jun;17(6):7595-7602.  [Abstract]

    Representative images show the expression levels of α SMA, calponin and osteopontin (OPN) protein.

    U0126-EtOH purchased from MCE. Usage Cited in: Cell Physiol Biochem. 2018;50(4):1522-1534.  [Abstract]

    Western analysis of effect of U0126 on Nell-1-induced changes in p-ERK, Runx2, OPG and Col-I protein expression in MC3T3-E1 preosteoblasts on Ti surfaces.

    U0126-EtOH purchased from MCE. Usage Cited in: Cancer Lett. 2017 Feb 16;393:22-32.  [Abstract]

    Effects of p38 MAPK inhibitor (SB203580), ERK inhibitor (U0126), JNK inhibitor (SP600125), caspase inhibitor (Z-VAD-FMK) and NAC on SGC-7901 and MGC-803 treated with DOX/VCPA combination treatment. VCPA pretreatment strategy is the same as above. SB203580 (20 μM), U0126 (10 μM), SP600125 (20 μM), Z-VAD-FMK (10 μM) and NAC (5 mM) are treated 2 h before DOX (2 μg/mL) added into the culture, respectively. MAPK pathway protein levels are determined.

    U0126-EtOH purchased from MCE. Usage Cited in: Free Radic Biol Med. 2017 Nov;112:49-59.  [Abstract]

    Cells are pre-treated with ERK (U1026) and p38 (SB203580) inhibitors, followed by GL-V9 treatment for 24 h. Western blot is performed to analyze NAG-1 expression.

    U0126-EtOH purchased from MCE. Usage Cited in: Cell Signal. 2017 Jan 16;32:48-58.   [Abstract]

    Western blotting showing the hepaCAMexpression and the phosphorylation level of STAT3, ERK and AKT in cells treated with IL-6 (20 ng/mL) for 24 h with or without the pretreatment of two respective inhibitors, Stattic (10 μM) and U0126 (5 μM).

    U0126-EtOH purchased from MCE. Usage Cited in: Cell Cycle. 2017 Apr 3;16(7):714-722.  [Abstract]

    Proliferation of OPCs by AST induced calcium signaling and phosphorylated ERK1/2. p-ERK levels decreased after Cx47 siRNA treatment and U0126-mediated ERK1/2 inhibition. The results of Western blotting show that U0126 causes a marked decrease in ERK1/2 phosphorylation

    U0126-EtOH purchased from MCE. Usage Cited in: Oncotarget. 2017 May 30;8(47):82027-82036.  [Abstract]

    U0126 and MEK162 block ERK activation (p-ERK1/2) in CZ415-treated U2OS cells.

    U0126-EtOH purchased from MCE. Usage Cited in: Oncotarget. 2017 May 16;8(20):33807-33826.  [Abstract]

    U0126 inhibits ERK1/2 activation in the kidney of hyperuricemic rats. Rat model of HN is established by feeding with adenine and potassium oxonate daily. In some rats, U0126 are simultaneously administrated intraperitoneally. After 28 days, the kidneys are taken for immunoblot analysis of p-ERK1/2, ERK1/2 or GAPDH.

    U0126-EtOH purchased from MCE. Usage Cited in: Oxid Med Cell Longev. 2017;2017:7426458.  [Abstract]

    Representative immunoblot analysis of p53, p16, p21, and retinoblastoma protein (Rb) in NP cells.

    U0126-EtOH purchased from MCE. Usage Cited in: Oxid Med Cell Longev. 2017;2017:6175841.  [Abstract]

    Involvements of MAPK signaling pathway in CPS-induced apoptosis in ALI cultures of sheep bronchial epithelial cells. Cells are pretreated with U0126 (an ERK1/2 inhibitor, 10?μM) for 1?h, followed by exposure to CPS (100?ng/mL) or MO (MOI = 30) for 48?h. Cell lysates are subjected to Western blotting analysis using indicated antibodies.

    U0126-EtOH purchased from MCE. Usage Cited in: ACS Chem Neurosci. 2015 Jan 21;6(1):130-7.  [Abstract]

    U0126 protects PC12 cells against H2O2-induced cell death. Western blot of ERK phosphorylation demonstrates that the MEK inhibitors U0126, GSK1120212 and Pimasertib are effective in blocking ERK phosphorylation under complete media, while U0124 results in slight ERK inhibition compared to DMSO control. Serum starvation results in lack of ERK phosphorylation in all conditions.

    U0126-EtOH purchased from MCE. Usage Cited in: J Mol Cell Cardiol. 2015 Dec;89(Pt B):268-79.  [Abstract]

    Dose response of MAPK and Akt inhibitors on cardiac fibroblast-derived exosomes (Exo)-induced activation of MAPKs and Akt. Neonatal rat cardiomyocytes are treated with or without Exo (50 μg/mL), U0126, SP600125, MK-2206, and SB023580 for 20 min and subjected to Western blot analysis. The results are from 4 separate experiments.

    查看 MEK 亞型特異性產(chǎn)品:

    • 生物活性

    • 純度 & 產(chǎn)品資料

    • 參考文獻

    生物活性

    U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC50s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor[1][2][3][4].

    IC50 & Target[1]

    MEK2

    60 nM (IC50)

    MEK1

    70 nM (IC50)

    體外研究
    (In Vitro)

    Treatment with U0126-EtOH (U0126) efficiently reduces progeny virus titers of all tested strains in A549 cells. While nM concentrations of U0126-EtOH are efficient to reduce H1N1v and H5N1 (MB1), μM concentrations of U0126-EtOH are required to reduce the virus titer of H5N1 (GSB) and H7N7. The EC50 values for U0126-EtOH against H1N1v are 1.2±0.4 μM in A549 cells and 74.7±1.0 μM in MDCKII cells[2].
    Rat hepatocarcinoma cells (FAO) stimulated by fetal calf serum (FCS) exhibits a significant proportion in S phase (32.62%) whereas U0126-EtOH (U0126) strongly decreases the proportion of cells in S phase (9.92%) and increases the proportion of cells in G0-G1 phase and to a lesser extent in G2/M[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[2]

    Cell Line: A549 and MDCK II cells.
    Concentration: 0.001-1000 μM.
    Incubation Time: 48 h.
    Result: The EC50 values for U0126 against H1N1v were 1.2 ± 0.4 μM in A549 cells and 74.7 ± 1.0 μM in MDCKII cells
    體內(nèi)研究
    (In Vivo)

    Mice are treated daily with U0126-EtOH (U0126; i.p., 10.5 mg/kg). In control experiment, tumor sizes are constant or slightly increase all over the kinetic. At the opposite, in all U0126-EtOH experiments, engraftment and early tumor growth are significantly decreased. Furthermore, a 60-70% reduction in the volume of tumors treated with U0126-EtOH is obtained 9 days after injection and thereafter[3].
    Rats are subjected to 120 minutes transient middle cerebral artery occlusion (tMCAO) and thereafter treated with the U0126-EtOH (U0126; i.p., 30 mg/kg) at 0 and 24 hours of reperfusion. After treatment with U0126-EtOH, the vasoconstriction to S6c is markedly reduced[4].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Athymic female nude mice (SWISS, nu/nu)[3].
    Dosage: 10.5 mg/kg.
    Administration: Intraperitoneal injection daily.
    Result: Inhibited tumor growth.
    Animal Model: Twelve-week-old female Wistar rats (250 to 265 g)[4].
    Dosage: 30 mg/kg.
    Administration: Intraperitoneally.
    Result: The vasoconstriction to S6c is markedly reduced.
    分子量

    426.56

    Formula

    C20H22N6OS2
    CAS 號
    性狀

    固體

    顏色

    White to light brown

    運輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性數(shù)據(jù)
    細胞實驗： 

    DMSO 中的溶解度 : 50 mg/mL (117.22 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    Ethanol 中的溶解度 : 2.38 mg/mL (5.58 mM; 超聲助溶)

    H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 2.3443 mL 11.7217 mL 23.4434 mL
    5 mM 0.4689 mL 2.3443 mL 4.6887 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲存時，請在1年內(nèi)使用， -20°C儲存時，請在6個月內(nèi)使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗：

    請根據(jù)您的 實驗動物和給藥方式 選擇適當?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (4.88 mM); 澄清溶液

      此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (4.88 mM); 澄清溶液

      此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

    以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

    • 方案 一

      請依序添加每種溶劑： 0.5% CMC-Na/saline water

      Solubility: 5 mg/mL (11.72 mM); 懸濁液; 超聲助溶

    動物溶解方案計算器
    請輸入動物實驗的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    只
    由于實驗過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計算結(jié)果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.41%

    參考文獻

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲存時，請在1年內(nèi)使用， -20°C儲存時，請在6個月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO 1 mM 2.3443 mL 11.7217 mL 23.4434 mL 58.6084 mL
    5 mM 0.4689 mL 2.3443 mL 4.6887 mL 11.7217 mL
    DMSO 10 mM 0.2344 mL 1.1722 mL 2.3443 mL 5.8608 mL
    15 mM 0.1563 mL 0.7814 mL 1.5629 mL 3.9072 mL
    20 mM 0.1172 mL 0.5861 mL 1.1722 mL 2.9304 mL
    25 mM 0.0938 mL 0.4689 mL 0.9377 mL 2.3443 mL
    30 mM 0.0781 mL 0.3907 mL 0.7814 mL 1.9536 mL
    40 mM 0.0586 mL 0.2930 mL 0.5861 mL 1.4652 mL
    50 mM 0.0469 mL 0.2344 mL 0.4689 mL 1.1722 mL
    60 mM 0.0391 mL 0.1954 mL 0.3907 mL 0.9768 mL
    80 mM 0.0293 mL 0.1465 mL 0.2930 mL 0.7326 mL
    100 mM 0.0234 mL 0.1172 mL 0.2344 mL 0.5861 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    U0126-EtOH
    目錄號：
    HY-12031
    需求量：